Outlook Therapeutics, Inc. Income Statement
OTLK|6 years of annual SEC 10-K data (FY2016-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Outlook Therapeutics, Inc. reported $1M in revenue and $75M in net loss for FY2025. Revenue has declined at a 13.5% compound annual rate over the past 9 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $8.1M | $3.1M | $3.8M | $3.0M | $5.2M |
| Cost of Revenue | $1.4M | - | - | - | - | - |
| Gross Profit | $57.2K | - | - | - | - | - |
| SG&A Expense | $29.9M | $9.4M | $14.2M | $15.9M | $21.6M | $12.9M |
| R&D Expense | $41.8M | $23.8M | $18.5M | $23.8M | $32.8M | $38.9M |
| Operating Income | -$71.7M | -$36.3M | -$29.6M | -$35.9M | -$51.3M | -$46.6M |
| Interest Expense | -$3.2M | $3.5M | $3.9M | $5.6M | $1.9M | $2.3M |
| Income Tax | $2.8K | -$3.4M | -$3.6M | $501.5K | $103.0K | -$190.1K |
| Net Income | -$75.4M | -$34.5M | -$30.1M | -$38.8M | -$53.3M | -$47.4M |
| EPS (Basic) | -$4.06 | - | - | -$1.67 | -$3.67 | - |
| EPS (Diluted) | -$4.06 | -$1.98 | -$9.74 | -$1.80 | -$3.67 | -$5.43 |
| Shares Outstanding | 23.9M | 28.6M | 9.0M | 24.9M | 22.8M | 9.4M |
| Gross Margin | 4.0% | - | - | - | - | - |
| Operating Margin | -5072.6% | -445.6% | -960.1% | -941.4% | -1723.3% | -892.1% |
| Profit Margin | -5331.8% | -423.8% | -974.6% | -1019.3% | -1788.9% | -908.1% |